Evidence map›Paper›PMID 40490917›Full record

ArticleJournal of proteome research2025

Low-Abundance Serum Protein Biomarker Candidates for HCC in Patients with Liver Cirrhosis.

Muhammad Salman Sajid, Rency S Varghese, Alexander Kroemer, Habtom W Ressom

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammad Salman SajidDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States.
Rency S VargheseDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States.
Alexander KroemerMedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, D.C. 20057, United States.
Habtom W RessomDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States.ORCID 0000-0001-9296-2132

Funding

Systems Metabolomics for Biomarker DiscoveryR35GM141944 · NIGMS · GEORGETOWN UNIVERSITY · PI RESSOM, HABTOM W · 2021 to 2025
$2.4M
NIGMS NIH HHS R35 GM141944
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, often presenting diagnostic challenges in patients with underlying liver cirrhosis (CIRR). In this study, we employed both untargeted and targeted analysis of low-abundance serum proteins to identify potential biomarkers for HCC. In the untargeted study, we identified 15 proteins that exhibited statistically significant differential expression in HCC vs CIRR. In the targeted study, we confirmed differential expression of retinol-binding protein 4 (

Indexed as

Biomarkers, TumorBlood ProteinsCarcinoma, HepatocellularLiver CirrhosisLiver NeoplasmsFemaleHumansMaleMiddle AgedRetinol-Binding Proteins, PlasmaROC CurveBiomarkers, TumorBlood ProteinsRBP4 protein, humanRetinol-Binding Proteins, Plasmabiomarkerliver cancerlow abundance proteinnano-LC-MS/MSserum

Identifiers

PMID40490917
PMCPMC12288100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.